Addison Advisors LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 7.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 619 shares of the conglomerate’s stock after selling 51 shares during the quarter. Addison Advisors LLC’s holdings in Danaher were worth $142,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the business. AMF Tjanstepension AB purchased a new position in Danaher in the third quarter valued at about $5,923,000. Howard Capital Management Group LLC boosted its holdings in shares of Danaher by 4.1% in the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after buying an additional 48 shares in the last quarter. Allworth Financial LP grew its position in shares of Danaher by 6.1% in the 3rd quarter. Allworth Financial LP now owns 5,337 shares of the conglomerate’s stock worth $1,484,000 after buying an additional 307 shares during the last quarter. Arkadios Wealth Advisors raised its stake in shares of Danaher by 1.8% during the 3rd quarter. Arkadios Wealth Advisors now owns 3,572 shares of the conglomerate’s stock worth $993,000 after acquiring an additional 64 shares in the last quarter. Finally, Inscription Capital LLC lifted its position in Danaher by 75.5% during the third quarter. Inscription Capital LLC now owns 1,981 shares of the conglomerate’s stock valued at $551,000 after acquiring an additional 852 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.
Insider Activity at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Danaher
Danaher Stock Down 0.2 %
Shares of DHR stock opened at $210.65 on Wednesday. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The stock has a market cap of $150.56 billion, a P/E ratio of 39.90, a P/E/G ratio of 2.66 and a beta of 0.83. The stock has a 50 day moving average of $225.79 and a 200 day moving average of $246.04. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the company posted $2.09 earnings per share. As a group, sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. Danaher’s dividend payout ratio (DPR) is 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Top Stocks Investing in 5G Technology
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Stock Analyst Ratings and Canadian Analyst Ratings
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.